Biotech IPO Pricing Forecasts: OSA performances and pricing, investment strategy (Two master hands controlling Biotech IPO stock prices)

This column recommended buy IPO stocks after 50 % correction strategy made up to 500 % gain for  Celera ( drop from 250 to 130  back to 200 and split, recnet plunge from 150 to 55 in May, and rebound to 140) DNA down ftom 200 to 100 and recent plunge to 100 and rebound to 150

All stocks, the Blue chips IPO, the hitechs and internet IPO stock prices are determined by supply, demand, and investors sentiment, to put more specifically, are related to central banks monetary policy impact on the economy and the financial markets.

Dr. Warren Huang have developed thousands of these relationship for tracking last 20 years global economy, stocks prices with average error below 1.5 %, It predicted the Dow crash in 1987, last Sept. LTCM recent new high of 11300 and this week retreat to 10000,  Bubble appear again as Dr. Huang accurate prediction buy biotech, IT share as Nasdaq around 3000 in May, these stocks more than doubled . Bubble will burst, stock prices compression again as more earning decline warning lead to markets plunge to new low before Aug:
IPO and internet bubble burst in Apr 2000, after Greenspan 5 interest rate hikes to cooloff overheated stocks, housing markets resulted wealth effect, excessive consumer, business demand. Nasdaq plunge 35 % to 3200, Dow plunge 700 single day, most  IPO internet , BIOTECHstocks soared 1000 %, plunged below 75 % to 90 %  AND BELOW THEIR ipo PRICES

For biotech stock index are related to US Fed money supply growth, interest rate and investor sentiment (Nasdaq index), as for individual BIOTECH.. IPO stock prices, they are related to the  stock and Nasdaq index (investor sentiment in internet) and corporate revenue and earning outlook (depend on  NEW DRUG DEVELOPEMENT, stage of clinical trials COMMERCIALIZATION, PROFIT, MARGIN, MARKET SHARES   Biotec   were extremely volatile and overpriced by the publicity of completion of Genome, mostly from CELERA, We acurately predicted  1999 Dec  and early this year on sina.com and this website that all these bubble will burst: down 50-90 % to below 100  and price compression to 40-60 range  correction earlier this year:
Dr. Huang accurately predicted May 8, 2004 to Silicon Valley biotech investors on biotech IPO in 2004
are very depend upon Nasdaq ( investors sentiment )and clinical trials, corporate earning.
as investors sentiment follow Nasdaq drop from 2150 to 1750, Biotech IPO plunge below  0.5  for before clinical trials one and 1.0-4.0 for clinical one, and 1- 10 for stage two, 10-30 for stage 3, 30- 60 for patent approval, commercialization
IPO investment strategy:
Biotech genome star Celera and HGSI plunge from 250 to 41 as Nasdaq plunge to 2250 in  Dec2000 ,  accurately predicted by Dr Huang recommended to buy biotech shares,   These bubble will burst again as Nasdaq plunge to 1500, will be another buy opportunities
These stock are still under corrections in the weeks ahead: all stocks with poor earning outlook will be drop  to below  35 for (DNA) deflated and compressed to 10-20 (CRA) range. Those with widening loss will be down to 50 %  below  IPO prices. Then will will see  buying opportunities 

Biotech stocks IPO prices OSA forecasts

Dr. Huang accurately predicted May 8, 2004 to Silicon Valley biotech investors on biotech IPO in 2004
are very depend upon Nasdaq ( investors sentiment )and clinical trials, corporate earning.
as investors sentiment follow Nasdaq drop from 2150 to 1750, Biotech IPO plunge below  0.5  for before clinical trials one and 1.0-4.0 for clinical one, and 1- 10 for stage two, 10-30 for stage 3, 30- 60 for patent approval, commercialization

Over 30 million China, Taiwan government, banking, finance, corporate CEO, fund managers, analyst, traders, investors have been benefited by my analysis on China's 12 cities , Taiwan , US silicon Valley TV, radio daily, weekly commentary , and workshops since 1987